Company intelligence / Profile preview

AVIR Green Hills Biotechnology AG

Ownership: Private
Development stage: Phase 2

Overview

The company developed deltaFLU, an influenza vaccine that showed significant increase in influenza-specific antibodies in a Phase I/II clinical study with 80 adults. The vaccine was found to be effective and safe, with side effects not substantially differing from the placebo group[4].

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccinesLive attenuated vaccinesIntranasal vaccines
Industry: Biotech

Drug pipeline

2 assets

deltaFLU

Phase 2

Indications: Seasonal influenza

1 more asset in the full pipeline.

Request access →

Partnerships

Negotiations with companies in China and India[4]

Beyond the preview

Go deeper on AVIR Green Hills Biotechnology AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVIR Green Hills Biotechnology AG.

Explore the full profile